Saturday 17 October 2026 Export CODX’s income statement to Excel — free account

Co-Diagnostics, Inc.

Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.

0.65 0.07 −9.72%

Follow CODX

Alert me

Market cap: $5.3M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: 2/9
Altman Z: −9.74
Beneish M: 2.24
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.32

Revenue 0.72

Net Income (47.06)

Free Cash Flow (27.47)

Net Debt (3.65)

Current Ratio 1.81

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.42)

P/S ratio 3.88

P/B ratio 0.22

Past 5Y EPS Growth —

This Y EPS Growth 91.21%

Next Y EPS Growth 73.23%

Next Y revenue growth 5.06%

Next 5Y EPS Growth 80.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 32.39%

10-year low 10-year high

P/B against its own 10 years 5.74%

10-year low 10-year high

EV/FCF against its own 10 years 1.60%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	59	30	12	4
Receivables	0	0	0	0
Inventory	2	1	1	1
Other	—	—	—	—
	62	32	14	5

	2023	2024	2025	Q'26
Payables	1	3	2	1
ST’ Debt	—	—	—	—
Other	1	1	0	0
	6	7	4	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(61.60%)	(73.70%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(20.92%)	(43.52%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	0	3	1	0	4
’23	1	0	2	4	7
’22	23	5	5	1	34
’21	20	27	30	20	98
’20	2	24	22	27	75

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(9)	(8)	(6)	(6)	(29)
’24	(8)	(5)	(7)	(8)	(29)
’23	(6)	(6)	(6)	(5)	(22)
’22	8	2	1	(4)	7
’21	12	12	12	5	41
’20	(1)	1	9	20	28

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(9)	(9)	(6)	(6)	(30)
’24	(9)	(5)	(7)	(8)	(30)
’23	(6)	(6)	(6)	(5)	(23)
’22	7	1	1	(4)	5
’21	12	12	11	5	40
’20	(1)	1	8	19	27

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.06)	(1.46)	—	—	—
’25	(7.21)	(6.91)	(4.80)	(16.53)	(35.25)
’24	(9.31)	(7.51)	(9.61)	(10.81)	(37.24)
’23	(6.01)	(9.31)	(6.01)	(15.01)	(36.04)
’22	10.21	(2.40)	(1.20)	(20.42)	(13.51)
’21	7.81	9.91	11.41	7.51	36.94
’20	(1.50)	12.91	15.92	12.91	45.65

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	70.50	33.30	20.82	26.40	210.30	67.80	29.25	20.10	4.98	Analyst estimates 2026–2028 Powerpack
	High	—	205.50	199.80	113.10	929.70	620.55	303.30	99.90	66.90	46.50
People
People	Employees	—	15	20	23	37	101	145	155	132	115
	Revenue/emp, $m	—	0.00	0.00	0.01	2.01	0.97	0.24	0.04	0.03	0.01
Income, $m
Income, $m	Revenue	—	0	0	0	75	98	34	7	4	1
	Gross margin, %	0.00	96.10	76.44	47.67	77.75	88.18	83.98	38.57	74.48	64.27
	EBT	(2)	(7)	(6)	(6)	43	46	(19)	(38)	(38)	(49)
	EBT margin, %	0.00	(90,379.22)	(15,718.55)	(2,881.67)	57.10	46.62	(55.08)	(559.46)	(959.89)	(7,793.08)
	Net income	(2)	(7)	(6)	(6)	42	37	(14)	(35)	(38)	(47)
	Depreciation	0	0	0	0	0	0	17	1	1	1
Per share, $
Per share, $	Revenue	0.00	0.02	0.10	0.39	83.79	101.81	32.64	6.97	3.87	0.47
	Earnings	(5.86)	(19.07)	(14.57)	(10.81)	47.75	38.14	(13.51)	(36.04)	(37.24)	(35.25)
	Cash flow	(3.99)	(8.80)	(9.81)	(9.90)	31.65	42.73	6.27	(22.60)	(28.83)	(21.90)
	Capex	(0.04)	(0.35)	(0.10)	(0.20)	(0.87)	(0.70)	(1.36)	(1.40)	(0.74)	(0.53)
	Free cash flow	(4.02)	(9.15)	(9.91)	(10.10)	30.78	42.03	4.90	(23.99)	(29.57)	(22.43)
	Book value	(9.10)	10.55	(2.55)	3.11	74.96	139.86	109.24	88.02	53.28	15.51
	Shares, m	0	0	0	1	1	1	1	1	1	1
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	6.50	6.97	0.00	0.00	0.00	0.00
	P/S	—	0.00	465.82	69.69	3.33	2.63	2.33	6.11	5.81	10.83
	P/B	—	7.85	0.00	8.62	3.72	1.92	0.69	0.48	0.42	0.33
	EV/Sales	—	0.00	442.01	65.53	2.70	1.71	(0.05)	(2.48)	(1.79)	(8.26)
	EV/FCF	—	(7.99)	(4.28)	(2.48)	7.34	4.15	(0.33)	0.72	0.23	0.17
Cash, $m
Cash, $m	Operating cash flow	(1)	(3)	(4)	(6)	28	41	7	(22)	(29)	(29)
	Capex	0	0	0	0	(1)	(1)	(1)	(1)	(1)	(1)
	Free cash flow	(1)	(3)	(4)	(6)	27	40	5	(23)	(30)	(30)
Balance, $m
Balance, $m	Working capital	(3)	4	(1)	1	64	103	89	56	25	10
	Total debt	0	—	2	—	—	—	0	—	—	—
	Net debt	(1)	(4)	(1)	(1)	(47)	(90)	(81)	(59)	(30)	(12)
	Shareholders’ equity	(3)	4	(1)	2	67	134	115	86	54	21
Returns, %
Returns, %	ROA	(64.74)	(233.60)	(201.81)	(328.81)	115.66	31.70	(10.06)	(32.36)	(47.38)	(106.21)
	ROIC	0.00	(902.71)	0.00	(436.34)	134.43	64.53	(50.70)	(97.18)	(103.83)	(358.57)
	ROE	(450.68)	(1,626.17)	(449.31)	(1,826.53)	124.14	36.45	(11.44)	(35.24)	(53.81)	(125.89)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
Median of peers	$5.3M	—	—	+17.61%	—	−6.68%	50.27%	(93.63%)

All 149 Medical Devices stocks →

Co-Diagnostics, Inc. (CODX) key facts

Concern: Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024.
Co-Diagnostics, Inc. (CODX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CODX traded at $0.65, a market capitalization of $5.3 million.
Return on equity was −125.9% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.74 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.